Gyre Therapeutics Inc. (GYRE) — Cash Flow Quality Index
Gyre Therapeutics Inc. (GYRE) has a Cash Flow Quality Index of 0.79x as of September 2025. Operating cash flow of $4.68 Million is below net income of $5.94 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Gyre Therapeutics Inc. debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Gyre Therapeutics Inc. Cash Flow Quality Index (2006–2025)
Historical Cash Flow Quality Index for Gyre Therapeutics Inc. across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Gyre Therapeutics Inc. (GYRE) cash conversion ratio.
Annual Cash Flow Quality Index for Gyre Therapeutics Inc. (2006–2025)
Year-by-year earnings quality comparison for Gyre Therapeutics Inc..
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | $1.01 Million | $9.88 Million | ▲ +150.3% |
| 2024 | -0.20x | $-3.64 Million | $17.90 Million | ▼ -108.2% |
| 2022 | 2.47x | $10.68 Million | $4.31 Million | ▼ -80.5% |
| 2010 | 12.69x | $138.30 Million | $10.90 Million | ▲ +368.9% |
| 2006 | -4.72x | $-9.89 Million | $2.10 Million | — |